AZOLID Drug Patent Profile
✉ Email this page to a colleague
When do Azolid patents expire, and when can generic versions of Azolid launch?
Azolid is a drug marketed by Sanofi Aventis Us and is included in two NDAs.
The generic ingredient in AZOLID is phenylbutazone. There are nine drug master file entries for this compound. Additional details are available on the phenylbutazone profile page.
Summary for AZOLID
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 118 |
Patent Applications: | 3,812 |
Formulation / Manufacturing: | see details |
DailyMed Link: | AZOLID at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for AZOLID
US Patents and Regulatory Information for AZOLID
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | AZOLID | phenylbutazone | CAPSULE;ORAL | 087260-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | AZOLID | phenylbutazone | TABLET;ORAL | 087091-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |